Anti-alpha-synuclein antibodies and methods of use thereof
WO2020243635A1
Modified release formulation of a pyrimidinylamino-pyrazole compound, and methods of treatment
WO2020210684A1
Compounds, compositions and methods
WO2020206320A1
Formulations of protein molecules comprising iduronate 2-sulfatase
WO2020181247A1
Compounds, compositions and methods
WO2020172450A1
Anti-trem2 antibodies and methods of use thereof
TW202045164A
Compounds, compositions and methods
WO2020167994A1
Compounds, compositions and methods
WO2020123511A2
Lysosomal storage disorder biomarkers and methods of use thereof
WO2020112889A2
Methods for treating dysregulated lipid metabolism
CA3115345A1
Methods for treating and monitoring progranulin-associated disorders
TW202017947A
Anti-her2 polypeptides and methods of use thereof
AU2019320803A1
Engineered bispecific proteins
AR115780A2
AZEPINES AND CONDENSED OXAZEPINES AS PROTEIN KINASE 1 INHIBITORS, THE PHARMACEUTICAL COMPOSITION THAT INCLUDES THEM AND THEIR USE IN THE TREATMENT OF PROTEIN KINASE 1 MEDIATED DISEASES
AR115565A1
FUSION PROTEINS INCLUDING PROGRANULIN
AU2019288212A1
Fusion proteins comprising progranulin
EP3768660A1
Modulators of eukaryotic initiation factor 2
KR20200119251A
Transferrin receptor-binding polypeptides and uses thereof
BR112020012611A2
PROCESS FOR THE PREPARATION OF PYRIMIDINYL-4-AMINOPYRAZOLE COMPOUNDS
BR112020010215A2
polymorphs and solid forms of a pyrimidinylamino-pyrazole compound and production methods
